Degenerative Disc Disease Clinical Trial
— FUSEOfficial title:
Safety and Effectiveness of Posterior Cervical Stabilization System (PCSS) as an Adjunct to Posterior Cervical Fusion, When Used in Combination With ACDF in Treatment of Multi-level Cervical Degenerative Disease
Verified date | May 2023 |
Source | Providence Medical Technology, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will evaluate the safety and effectiveness of a device called "Posterior Cervical Stabilization System or PCSS" when used along with posterior cervical fusion (PCF) in combination with anterior cervical discectomy and fusion (ACDF) in the treatment of multi-level cervical degenerative disease.
Status | Active, not recruiting |
Enrollment | 236 |
Est. completion date | December 2025 |
Est. primary completion date | June 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Age 18-80 years (Skeletally Mature) 2. Indicated for ACDF treatment of degenerative disc disease (DDD) between and including C3-C7 at 3 contiguous levels 3. NDI Score of =15/50 4. Unresponsive to non-operative, conservative treatment (rest, heat, electrotherapy, physical therapy, chiropractic care and/or analgesics) 5. Reported to be medically cleared for surgery 6. Physically and mentally able and willing to comply with the Protocol, including the ability to read and complete required forms and willing and able to adhere to the scheduled follow-up visits and requirements of the Protocol. 7. Written informed consent provided by subject Exclusion Criteria: 1. Body Mass Index (BMI) greater than 40 kg/m2 2. Active systemic infection or infection at the operative site 3. History of or anticipated treatment for active systemic infection, including HIV or Hepatitis C 4. Previous trauma to the C3 to C7 levels resulting in significant bony or disco- ligamentous cervical spine injury that may prevent device placements 5. A prior spine surgery or pseudoarthrosis at the operative levels 6. Axial neck pain in the absence of other symptoms of radiculopathy or myeloradiculopathy justifying the need for surgical intervention 7. Symptomatic DDD or significant cervical spondylosis at more than three levels 8. Diagnosis of spondylolisthesis, grade >2 9. Overt (Segmental) instability measured as a movement on dynamic flex/ext x-rays >3.5 mm 10. Congenital bony and/or spinal cord abnormalities that affect spinal stability 11. Diagnosis of Paget's disease, osteomalacia or any other metabolic bone disease other than osteoporosis 12. Osteoporosis, defined as either the SCORE or MORES = 6 and a DEXA bone density measured T-score of = -2.5 13. Active malignancy or a history of any invasive malignancy (except non-melanoma skin cancer), unless treated with curative intent and without clinical signs or symptoms of the malignancy for at least five years 14. Has an uncontrolled seizure disorder 15. Use of epidural steroids within 14 days prior to surgery 16. A concomitant condition requiring daily, high-dose oral and/or inhaled steroids 17. Known allergy to titanium (Ti). 18. Fixed or permanent neurologic deficit related to the target treatment levels that cannot be improved with surgical decompression 19. Has, in the Investigator's opinion, any disease or condition that would preclude accurate clinical evaluation (e.g. neuromuscular disorders). 20. Is pregnant or nursing at time of screening, or with plans to become pregnant within the next three years. 21. A current or recent history (= 1 year prior to screening) of substance abuse (alcoholism and/or narcotic addiction) that required treatment. 22. Long term use (>6 months) of opioids (max. daily amount=120 mg morphine equivalents). 23. A mental illness or belongs to a vulnerable population, as determined by the investigator (e.g., prisoner or developmentally disabled), that would compromise ability to provide informed consent or compliance with follow-up requirements. 24. Any other condition or anatomy (e.g. fused facet) that makes posterior fusion treatment infeasible 25. Use of any other investigational drug or medical device within the last 30 days prior to surgery. 26. A pending personal litigation relating to spinal injury (worker's compensation is not exclusionary). 27. Anticipated or potential relocation greater than 50 miles that may interfere with completion of follow-up examinations. |
Country | Name | City | State |
---|---|---|---|
United States | LifeBridge Health - Sinai Hospital of Baltimore | Baltimore | Maryland |
United States | Bone and Joint Clinic of Baton Rouge | Baton Rouge | Louisiana |
United States | The University of North Carolina at Chapel Hill | Chapel Hill | North Carolina |
United States | Rush University Medical Center | Chicago | Illinois |
United States | Spine Colorado | Durango | Colorado |
United States | Scripps | Encinitas | California |
United States | Baylor College of Medicine | Houston | Texas |
United States | OrthoNorCal | Los Gatos | California |
United States | LSU Health | New Orleans | Louisiana |
United States | The Orthopaedic Institute | Paducah | Kentucky |
United States | Thomas Jefferson University | Philadelphia | Pennsylvania |
United States | Barrow Neurological Institute | Phoenix | Arizona |
United States | Pinehurst Surgical Clinic | Pinehurst | North Carolina |
United States | Beaumont Health | Royal Oak | Michigan |
United States | Spine Institute of Louisiana | Shreveport | Louisiana |
United States | Inspira Health Network | Vineland | New Jersey |
United States | Atlantic Neurosurgical & Spine Specialists | Wilmington | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Providence Medical Technology, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Superiority in Fusion Success in CCF (treatment) compared to ACDF (control) | An individual subject is considered a fusion success if there is evidence of bridging trabecular bone across endplates and < 2° total angular motion | 12 months | |
Secondary | Non-inferiority Composite Safety Success in CCF (treatment) compared to ACDF (control) | An individual subject is considered a success if all of the following safety criteria are met:
Fusion success - as defined by evidence of bridging trabecular bone across endplates and < 2° total angular motion Improvement in Neck Disability Index (NDI) Improvement in Neurological function Absence of secondary surgical interventions (SSI) |
24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04848376 -
Post-Market Clinical Follow-up Study of A-SPINE's Products
|
||
Active, not recruiting |
NCT05114135 -
TLIF Osteo3 ZP Putty Study (Also Known as the TOP Fusion Study)
|
N/A | |
Suspended |
NCT04735185 -
Stem Cells vs. Steroids for Discogenic Back Pain
|
N/A | |
Withdrawn |
NCT03223701 -
Efficacy of Using Solum IV and BMC With GFC in TLIF
|
Phase 4 | |
Completed |
NCT04057235 -
Retrospective Review of Integrity Implants FlareHawk® for Lumbar Fusion
|
||
Not yet recruiting |
NCT06000319 -
Natural Matrix Protein™ (NMP™) Fibers in Cervical and Lumbar Interbody Fusion
|
||
Active, not recruiting |
NCT02969616 -
Trinity Elite in Lumbar Fusion
|
||
Completed |
NCT02558621 -
New Robotic Assistance System for Spinal Fusion Surgery
|
N/A | |
Completed |
NCT02104167 -
Retrospective/Prospective Data Collection on the LDR ROIC Interbody Fusion Device With VerteBRIDGE Plating
|
||
Terminated |
NCT00974623 -
Bone Graft Materials Observational Registry
|
N/A | |
Completed |
NCT00965380 -
Trinity Evolution in Posterior or Transforaminal Lumbar Interbody Fusion (PLIF/TLIF)
|
||
Completed |
NCT00996073 -
Safety and Preliminary Efficacy Study of NeoFuse in Subjects Requiring Lumbar Interbody Fusion
|
Phase 2 | |
Completed |
NCT00758719 -
Evaluate Effectiveness of the Biomet Lumbar Spinal Fusion System
|
||
Completed |
NCT00165893 -
Comparison of IDD Therapy and Non-surgical Treatment for Low Back Pain Caused by Degenerative Disc Disease
|
Phase 4 | |
Terminated |
NCT01494493 -
Pivotal Study of rhBMP-2/ACS/Allograft Bone Dowel for Anterior Lumbar Interbody Fusion in Patients With Symptomatic Degenerative Disc Disease
|
N/A | |
Recruiting |
NCT04727385 -
Intervertebral DXM Gel Injection in Adults With Painful Lumbar Degenerative Disc Disease
|
N/A | |
Completed |
NCT04849429 -
Intra-discal Injection of Platelet-rich Plasma (PRP) Enriched With Exosomes in Chronic Low Back Pain
|
Phase 1 | |
Recruiting |
NCT04469387 -
Preventive Effect of Limited Decompression on Adjacent Segment Following Posterior Lumbar Interbody Fusion
|
N/A | |
Recruiting |
NCT04056520 -
Clinical and Radiological Outcomes of Posterior Cervical Fusion With Medtronic Infinity Occipitocervical-Upper Thoracic (OCT) System
|
||
Completed |
NCT04119466 -
Stabilizing Training in Degenerative Disc Disease
|
N/A |